A peer-grade clinical and scientific reference for the SignalOME paradigm — a mechanism-first framework for organizing chronic disease, aging, and regeneration around ten dysregulated signaling networks. Written for physicians who treat the network rather than the diagnosis.
Modern medicine is a magnificent machine built for acute, single-cause illness, and in that arena it is unrivaled. But the majority of what walks through a twenty-first-century clinic door is not acute, not single-cause, and not curable in that classical sense — it is chronic, multi-system, and signaling-driven.
The disease model — one symptom cluster, one diagnostic code, one drug, one specialist — produces a recognizable failure mode: the patient on six medications who feels worse every year. The interventions are not individually wrong; the frame is. Downstream phenotypes are being treated as if they were upstream causes.
The SignalOME paradigm identifies ten intracellular and intercellular signaling networks that, when dysregulated, produce the recognizable patterns of chronic disease and biological aging. Each network is measurable with a targeted biomarker panel, modulable with tools accessible to a precision-medicine practice, and causally upstream of multiple named diseases.
fibromyalgia · hypothyroidism · osteoarthritisVerbs are tractable. Nouns are not.
The 2023 update of The Hallmarks of Aging by López-Otín and colleagues — twelve hallmarks now including chronic inflammation and dysbiosis — is the closest mainstream alignment with what the SignalOME formalizes for clinical use. The hallmarks are descriptive; the SignalOME is operational: each hallmark maps to one or more signalomes with a defined workup, decision tree, and intervention pathway.
Every patient's clinical picture is a vector across the ten signalomes — the patient's Signalome Dysregulation Phenotype (SDP). The work of the SignalOME-grounded physician is to elicit the story, map it to a hypothesized SDP, confirm with targeted biomarkers, synthesize dominant and contributory signalomes, and sequence interventions upstream-first — almost always Inflammatome and Metabolome before Senescence or Regeneratome.
An index of the ten signaling networks. Each opens to its mechanism of action, a Tier-1 biomarker panel, a tiered modulation strategy, and anchoring literature.
NF-κB is the transcriptional integrator of inflammatory signaling, activated by TLRs, TNF receptors, IL-1R, oxidative stress, and DAMPs/PAMPs. Chronic low-grade NF-κB activation drives the phenotype Franceschi named inflammaging.
NLRP3 inflammasome assembly — sensor + ASC + caspase-1 — cleaves pro-IL-1β and pro-IL-18 and triggers gasdermin-D-mediated pyroptosis. NLRP3 is metabolically gated: mitochondrial ROS, succinate, ceramides, cholesterol crystals, and uric acid all prime it.
The metabolic bridge: visceral adiposity → free fatty acid flux → TLR4 → NF-κB → insulin resistance → further adiposity. In late-stage dysregulation the Inflammatome and Metabolome behave as one network.
mTOR integrates amino acid, growth factor, and energy signals to drive anabolic processes. Chronic over-activation drives senescence, sarcopenic obesity, and cancer risk; mTORC1 inhibition by rapamycin extends lifespan across model organisms.
AMPK is the opposing energy-stress sensor, promoting autophagy, mitochondrial biogenesis, and fatty acid oxidation while suppressing mTOR. Metformin's geroprotective action is largely AMPK-dependent.
Sirtuins (SIRT1/3/6) are NAD⁺-dependent deacetylases governing metabolic homeostasis and mitochondrial biogenesis; activity depends on NAD⁺, which declines with age. The GH/IGF-1 axis drives growth — chronic elevation correlates with reduced lifespan.
HPA axis: chronic activation drives visceral adiposity, hippocampal atrophy, Th17 skew, and Inflammatome amplification. Diurnal cortisol abnormalities precede frank disease by years.
HPG axis: the perimenopausal and andropausal transitions are the most consequential predictable endocrine collapses in medicine. The KEEPS and ELITE trials reframed the timing hypothesis — estradiol within ~6 years of menopause confers benefit; later initiation does not. WHI harms (CEE+MPA) do not generalize to transdermal estradiol + micronized progesterone.
HPT axis: TSH-only screening misses conversion failures and rT3 elevation. Vitamin D is a secosteroid hormone, not a vitamin; target 40–60 ng/mL with K2 cofactor.
T-helper polarization governs autoimmunity, allergy, and tolerance. The Th17/Treg ratio rises with age and is linked to mortality; centenarians paradoxically down-regulate it and skew Treg toward IL-10.
Immunosenescence manifests as CD8⁺ effector accumulation, naïve T-cell depletion, CMV-driven memory inflation, and thymic involution — the cellular bridge to the Inflammatome.
Mucosal immunity (GALT) is the gateway between Microbiome and Immunome; barrier failure → LPS translocation → systemic NF-κB → Th17 expansion. LDN shifts Th17 toward Treg with reproducible signal across autoimmune conditions.
Wnt/β-catenin governs stem cell maintenance, tissue patterning, osteoblast differentiation, and — when dysregulated — fibrosis and oncogenesis.
TGF-β is Janus-faced: pro-regenerative in acute injury, pro-fibrotic in chronic exposure. Net effect depends on duration, tissue context, and concurrent signaling.
Orthobiologics: PRP composition matters — leukocyte-poor vs -rich, concentration factor, preparation, and timing all modify outcome. The RESTORE trial (JAMA 2021) showed no superiority of LR-PRP over saline in knee OA under its protocol; aggregate evidence for tendinopathy and selected OA phenotypes remains supportive with LP-PRP and appropriate selection.
Beyond the monoamine hypothesis: the dominant fast-signaling axes are glutamate (NMDA, AMPA, mGluR) and GABA. Chronic stress reduces GAD65/67 in prefrontal cortex, shifting the excitatory–inhibitory balance toward excitotoxicity.
Ketamine and esketamine work in hours by blocking NMDA receptors on interneurons, producing a glutamate surge that drives rapid plasticity through AMPA and BDNF-mTOR.
Kynurenine pathway: under inflammation, IDO/TDO divert tryptophan away from serotonin toward neurotoxic quinolinic acid. The kynurenine/tryptophan ratio is the chemical bridge from Inflammatome to depression.
Nrf2/Keap1 is the master regulator of phase-II detoxification and antioxidant response. Electrophilic stress modifies Keap1 cysteines, releasing Nrf2 to activate ARE-driven genes (NQO1, HO-1, GST, glutamate-cysteine ligase).
Glutathione: the GSH/GSSG ratio is the dominant intracellular redox buffer. GlyNAC restoration in older adults improves oxidative markers, mitochondrial function, and insulin sensitivity.
Mitohormesis: ROS are physiologic at low levels and pathologic at high levels. Nrf2 is best activated by intermittent challenge — exercise, sauna, fasting, cruciferous intake — not perpetual antioxidant flooding. Megadose vitamin E worsened outcomes in HOPE.
Bioelectric pattern formation: Levin's program at Tufts reframed bioelectricity from epiphenomenon to causal layer. Resting membrane potential (Vmem) in non-neural cells encodes morphogenetic information; ion channels and gap junctions form circuits that pattern regeneration and decay with aging.
PEMF — FDA-cleared for non-union fractures since 1979 — links to Wnt/β-catenin activation in osteoblasts and downregulation of TNF-α and IL-1β in OA chondrocytes. The Bioelectrome therefore acts through the Regeneratome and Inflammatome.
Photobiomodulation (600–1100 nm) activates cytochrome c oxidase, increasing ATP and modulating ROS — a Bioelectrome–Oxidatome bridge.
The microbiome is the interface through which the gut speaks to all the other signalomes.
SCFAs: butyrate is the primary colonocyte fuel, an HDAC inhibitor, and an IDO downregulator — modulating kynurenine flux (Neurotransmitome bridge). Bile acids: secondary bile acids agonize FXR and TGR5 (GLP-1 release, energy expenditure) — the Microbiome–Metabolome bridge.
Tryptophan: microbial indole derivatives are AhR ligands that fortify the barrier and regulate Th17/Treg — the Microbiome–Immunome bridge. LPS translocation: "leaky gut" → portal LPS → TLR4 → systemic NF-κB (Cani's metabolic-endotoxemia model).
Cellular senescence is irreversible cell-cycle arrest via p16INK4a/Rb and p21CIP1 pathways, triggered by telomere attrition, DNA-damage response, oncogenic stress, or mitochondrial dysfunction. Senescent cells resist apoptosis through upregulated pro-survival networks.
SASP — the senescence-associated secretory phenotype — is the proximate cause of most age-related tissue dysfunction; its cytokines propagate senescence and feed NF-κB inflammaging. Senescence and Inflammatome are functionally inseparable in late biology.
Senolytics selectively eliminate senescent cells by disabling pro-survival networks (D+Q; fisetin in investigation). Epigenetic clocks — GrimAge, DunedinPACE — provide composite biological-age biomarkers; GrimAge is the most robust mortality predictor.
A SignalOME-grounded encounter has five sequential stations. Each is structured, time-protected, and produces a defined output — a clinical methodology, not a checklist.
Sixty minutes minimum at intake. A chronological narrative in signaling language — onset patterns, triggers, family signal history, the patient's own theory.
Translate the story into a hypothesized SDP vector across the ten signalomes. Score each 0–3. Identify dominant and contributory networks.
Hypothesis-driven biomarker panels, not shotgun labs. Tier-1 per dominant signalome; imaging where signaling implicates structure.
Compute the confirmed SDP. Sequence interventions upstream-first. Define a 90-day intervention plan with measurable endpoints.
Quarterly recalibration. SignalOME medicine is iterative, not episodic. Re-measure, adjust, document trajectory.
The SDP is a 10-element vector, each signalome scored 0 (optimal) to 3 (severe). Six archetypal patterns recur in practice and guide intervention sequencing.
50–65 y, central adiposity, cognitive slowing, joint stiffness, lipid creep. hsCRP >3, IL-6 elevated, fasting insulin 12–18. The most common presenting SDP in executive populations.
45–55 y, sleep destruction, mood lability, brain fog, vasomotor instability, weight redistribution. A KEEPS/ELITE-window candidate for route-optimized estradiol + progesterone.
Three or more autoimmune diagnoses in one patient. Th17/Treg imbalance, zonulin elevation, dysbiosis on stool sequencing. LDN + barrier repair + targeted eliminations.
Tendinopathy, partial tears, early OA. A surgical candidate declining surgery. Pre-procedure systemic optimization before orthobiologic intervention drives outcome.
"Treatment-resistant" depression with hsCRP >3 and elevated kynurenine/tryptophan ratio. An inflammation-first approach often outperforms further psychotropic escalation.
70+ y, declining function, sarcopenia, delayed recovery. Resistance training + protein + creatine + selective senotherapy. Track grip, gait, GrimAge / DunedinPACE.
Composite, de-identified clinical illustrations of the paradigm in practice. These vignettes describe patterns and outcomes for educational purposes — they are not protocols, not individualized medical advice, and not a substitute for clinical judgment.
A patient in their early sixties carried five separate labels — early osteoarthritis, mild cognitive impairment, dyslipidemia, central adiposity, dysthymia — with no unifying story. The SignalOME workup identified a dominant Inflammatome (hsCRP and IL-6 elevated, GlycA high) with contributory Metabolome and early Senescence activation. An upstream-first plan produced normalization of inflammatory markers, body composition, cognitive metrics, and lipids across roughly 90 days. Five named problems resolved as one pattern.
Illustrative composite. Selection, sequencing, and monitoring detail are individualized in practice.
A patient roughly 18 months post-menopause presented with sleep destruction, vasomotor instability, mood lability, and a documented decline on cognitive screening, and had been offered an SSRI in place of hormone therapy on the basis of misapplied Women's Health Initiative concerns. She fell within the KEEPS/ELITE timing window; route-optimized bioidentical hormone therapy was associated with restored sleep architecture, recovered cognitive-screen performance, and a reduction in hsCRP over about twelve weeks.
Illustrative composite. The KEEPS/ELITE window and consent framework are applied case-by-case.
Hashimoto's thyroiditis, plaque psoriasis, and diarrhea-predominant IBS across three specialists. The working hypothesis — one pattern of Immunome and Microbiome dysregulation rather than three diseases — was consistent with elevated TPO antibodies, zonulin, a dysbiosis pattern, and vitamin D deficiency. An Immunome-first approach (titrated LDN, 4R barrier restoration, selected nutritional modulation) was associated with reduced TPO antibodies, psoriatic improvement, and GI normalization at six months.
Illustrative composite. LDN titration and contraindication screening are individualized.
A patient on a surgical pathway for presumed normal-pressure hydrocephalus underwent a SignalOME workup in parallel with — not instead of — continued surgical evaluation. The workup revealed a pattern dominated by Inflammatome, Hormonome (low vitamin D, suboptimal thyroid conversion), and microbiome dysbiosis. Upstream-first intervention was associated with substantial gait and cognitive improvement. Not all such cases respond this way; selection matters, and the paradigm does not displace surgical evaluation when clinically indicated — it adds a parallel assessment that occasionally reframes the case.
Illustrative composite. Parallel-evaluation ethics and selection criteria are applied case-by-case.
A representative selection of the 100+ peer-reviewed citations that anchor the paradigm across its ten domains. The framework operationalizes — rather than replaces — the biology described in the published literature.
A working glossary of SignalOME terminology in the canonical phrasing the framework uses internally. Alternate forms are noted where they exist in the literature.
Direct answers to questions physicians and informed readers commonly ask, written in canonical form so the framework can be cited accurately.
The SignalOME Paradigm is a mechanism-first clinical framework that organizes chronic disease, biological aging, and tissue regeneration around ten measurable, modulable signaling networks rather than around named disease diagnoses. The ten are the Inflammatome, Metabolome, Hormonome, Immunome, Regeneratome, Neurotransmitome, Oxidatome, Bioelectrome, Microbiome-Signalome Interface, and Senescence Signalome. Each has a defined biomarker panel and a tiered modulation strategy. It was developed by Adam Sewell, MD and Angelo Mattalino, MD.
The paradigm was co-developed by Adam Sewell, MD and Angelo Mattalino, MD. Their collaboration began through the American Arthritis Foundation, where the framework was first formalized in white-paper form before being expanded into the full ten-signalome architecture and the S1–S5 workup.
Functional medicine pioneered systems-biology thinking in clinical practice. The SignalOME Paradigm extends that work in three specific ways: it identifies discrete signaling networks rather than open-ended root-cause concepts; it requires hypothesis-driven Tier-1 biomarker panels rather than broad shotgun testing; and it sequences interventions upstream-first based on documented mechanistic dependencies. It is tightly coupled to the regenerative-medicine and longevity literature, particularly the 2023 López-Otín Hallmarks of Aging consensus.
An SDP is a 10-element vector scoring each signalome from 0 (optimal) to 3 (severe dysregulation). It replaces the disease diagnosis as the organizing unit of care. Six archetypal patterns recur in practice: Inflammaging Executive, Perimenopausal Composite, Autoimmune Triad, Regenerative Orthopedic, Mood-Inflammatory, and Frail-Sarcopenic.
The framework is anchored in over 100 peer-reviewed citations spanning all ten signalomes — including Franceschi on inflammaging, Harrison on rapamycin, Barzilai on metformin, the KEEPS and ELITE hormone-timing trials, work on low-dose naltrexone, Hickson and Justice on senolytics, the RESTORE PRP trial, Levin on bioelectric signaling, and the 2023 López-Otín Hallmarks of Aging update. It operationalizes rather than replaces the underlying published biology. It is an organizing framework and decision-support reference, not a claim of proven efficacy for any specific protocol.
It is designed for the chronic, multi-system, signaling-driven conditions that dominate modern practice: chronic inflammatory and autoimmune disease, metabolic syndrome, the perimenopausal and andropausal transitions, inflammation-driven mood disorders, age-related musculoskeletal degeneration, sarcopenia and frailty, and cognitive decline. It does not displace acute-care or surgical medicine where those are clinically indicated.
The 2023 López-Otín update — twelve hallmarks now including chronic inflammation and dysbiosis — is the closest mainstream alignment with what the SignalOME formalizes. The hallmarks are descriptive; the SignalOME is operational. Each hallmark maps to one or more signalomes with a defined biomarker panel and intervention pathway.
Inflammaging, a term coined by Claudio Franceschi, describes chronic, sterile, low-amplitude systemic inflammation that underwrites cardiovascular disease, neurodegeneration, sarcopenia, insulin resistance, and frailty. It is driven by persistent NF-κB activation, NLRP3 assembly, and SASP cytokine release, and within the paradigm is the dominant late-life expression of the Inflammatome.
Low-dose naltrexone is naltrexone at 1.5–4.5 mg at bedtime — roughly one-tenth to one-twentieth of its addiction-medicine dose. At these doses it modulates microglial TLR4 and shifts the Th17/Treg balance toward tolerance, with reproducible clinical signal in fibromyalgia, Crohn's, MS, and CRPS. It is generally well-tolerated; vivid dreams in the first one to two weeks are common and self-limited, and it is contraindicated in active opioid therapy. It requires independent clinical evaluation and informed consent.
The approach rests on the KEEPS and ELITE timing hypothesis: estradiol initiated within roughly six years of menopause confers cardiovascular and, in some cohorts, cognitive benefit, while later initiation does not. The harms documented in the Women's Health Initiative reflected conjugated equine estrogens plus medroxyprogesterone in older women and are not generalizable to transdermal estradiol plus oral micronized progesterone in the appropriate window. The framework also requires the full thyroid panel rather than TSH-only screening.
The frameworks are complementary but distinct. Medicine 3.0 articulates the strategic shift from reactive to proactive longevity medicine and the central role of the "four horsemen." The SignalOME Paradigm provides a mechanistic operating system — ten signaling networks, the SDP language, and the S1–S5 workup — that can be understood as one rigorous implementation of that thesis.
This reference site teaches the architectural what — the networks, the SDP language, the workup structure, and the anchoring literature. The operational how — panel-selection thresholds, dose-titration logic, contraindication matrices, and monitoring cadence — is developed in the associated physician training program. This site itself is an educational reference and does not enroll patients or prescribe.
The reference content on this site is intentionally architectural. A companion physician curriculum develops the operational layer that converts the framework into clinical practice: panel-selection thresholds, dose-titration trees, contraindication matrices, monitoring cadence, and case-by-case judgment. It is open to MD and DO physicians in good standing.